| Code | CSB-RA723415MB3HU |
| Size | US$9799 |
| Order now | |
| Have Questions? | Leave a Message or Start an on-line Chat |
This recombinant monoclonal antibody is designed as a research-grade biosimilar to BMS-986179, targeting NT5E (ecto-5'-nucleotidase), also known as CD73. NT5E is an ectoenzyme that catalyzes the conversion of extracellular adenosine monophosphate to adenosine, playing a critical role in purinergic signaling and immune regulation. By generating adenosine in the tumor microenvironment, NT5E promotes immunosuppression through activation of adenosine receptors on immune cells, thereby inhibiting T cell and natural killer cell function. Elevated NT5E expression has been associated with poor prognosis in multiple cancer types, including triple-negative breast cancer, ovarian cancer, and melanoma.
BMS-986179 is a clinical-stage therapeutic antibody that blocks NT5E enzymatic activity, preventing adenosine accumulation and restoring anti-tumor immune responses. This biosimilar provides researchers with a valuable tool for investigating adenosine-mediated immunosuppression, studying NT5E biology in cancer and inflammatory contexts, and exploring combination immunotherapy strategies. It supports investigations into tumor immunity, checkpoint inhibition mechanisms, and metabolic regulation within the tumor microenvironment.
There are currently no reviews for this product.